abiraterone,[lu-177]-pnt2002,enzalutamide
janssen,pfizer,astellas,point biopharma
['pnt2002', 'splash', 'pnt2002 ']
results of the splash trial on the efficacy and safety of 177lu-pnt2002 were recently presented at #esmo2022, showing that 78% of patients remained event-free by the end of the trial. catch up on this presentation here: #psma #oncology #esmo
GU Oncology Now provides practical, timely, and relevant clinical information to practicing physicians treating genitourinary cancer within the United States.